ReviewCancer immunology research2014
Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic.
Review in Cancer immunology research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 66 citations in OpenAlex.
- An Insight into Immunological Therapeutic Approach against Cancer: Potential Anti-cancer Vaccines.Current genomics · 2025Review
- Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.Genes & diseases · 2023Review
- Establishing the applicability of cancer vaccines in combination with chemotherapeutic entities: current aspect and achievable prospects.Medical oncology (Northwood, London, England) · 2023Review
- Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies.Frontiers in oncology · 2023Review
- In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4Cancer immunology, immunotherapy : CII · 2022Article
- IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model.Frontiers in immunology · 2022Article
- A Cluster Analysis of Risk Factors for Cancer across EU Countries: Health Policy Recommendations for Prevention.International journal of environmental research and public health · 2021Article
- Inflammation-Induced Abnormal Expression of Self-molecules on Epithelial Cells: Targets for Tumor Immunoprevention.Cancer immunology research · 2020Article
- Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.Seminars in immunology · 2020Review
- Pentaerythritol-based lipid A bolsters the antitumor efficacy of a polyanhydride particle-based cancer vaccine.Nanomedicine : nanotechnology, biology, and medicine · 2019Article
- Single Dose of a Polyanhydride Particle-Based Vaccine Generates Potent Antigen-Specific Antitumor Immune Responses.The Journal of pharmacology and experimental therapeutics · 2019Article
- Strategies for developing and optimizing cancer vaccines.F1000Research · 2019Review
- Personalized cancer vaccines: adjuvants are important, too.Cancer immunology, immunotherapy : CII · 2018Review
- Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens: Nothing New in Spite of the Name.Cold Spring Harbor perspectives in biology · 2018Review
- Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS).JNCI cancer spectrum · 2018Article
- Cancer immunoprevention: from mice to early clinical trials.BMC immunology · 2018Review
- The dawn of vaccines for cancer prevention.Nature reviews. Immunology · 2018Review
- A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2018Review
- Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice.PloS one · 2018Article
- Immunotherapy for Breast Cancer: Current and Future Strategies.Current surgery reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Concerted efforts of tumor immunologists over more than two decades contributed numerous well-defined tumor antigens, many of which were promptly developed into cancer vaccines and tested in animal models and in clinical trials. Encouraging results from animal models were seldom recapitulated in clinical trials. The impediment to greater success of these vaccines has been their exclusive use for cancer therapy. What clinical trials primarily revealed were the numerous ways in which cancer and/or standard treatments for cancer could suppress the patient's immune system, making it very difficult to elicit effective immunity with therapeutic vaccines. In contrast, there is an extensive database of information from experiments in appropriate animal models showing that prophylactic vaccination is highly effective and safe. There are also studies that show that healthy people have immune responses against antigens expressed on tumors, some generated in response to viral infections and others in response to various nonmalignant acute inflammatory events. These immune responses do not appear to be dangerous and do not cause autoimmunity. Epidemiology studies have shown that these immune responses may reduce cancer risk significantly. Vaccines based on tumor antigens that are expressed differentially between tumors and normal cells and can stimulate immunity, and for which safety and efficacy have been proved in animal models and to the extent possible in therapeutic clinical trials, should be considered prime candidates for prophylactic cancer vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.